A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity

International Journal of Antimicrobial Agents

Volumn 34, Issue 2, 2009, Pages 177-180

  Brandi, Giorgio ^a   Rossi, Luigia ^a   Schiavano, Giuditta F ^a   Millo, Enrico ^b   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b Center of Excellence for Biomedical Research   (Italy)

Author keywords

Aciclovir homodimer; Anti HSV 1 activity; Antiviral prodrug

Indexed keywords

ACICLOVIR; HOMODIMER; THYMIDINE KINASE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ENCAPSULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SOLUBILITY; ERYTHROCYTE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; HERPESVIRUS 1, HUMAN; HUMANS; INHIBITORY CONCENTRATION 50; PLAQUE ASSAY; PRODRUGS; SOLUBILITY; VERO CELLS; VIRUS REPLICATION;

EID: 67349202045     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.02.025     Document Type: Article

References (15)

1. Whitley R.J., and Roizman B. Herpes simplex virus infections. Lancet 357 (2001) 1513-1518
2. Stanberry L.R., Jorgensen D.M., and Nahmias A.J. Herpes simplex viruses 1 and 2. In: Evans A.S., and Kaslow R. (Eds). Viral infections of humans: epidemiology and control. 4th ed. (1997), Plenum Publishers, New York, NY 419-454
3. Whitley R.J. Herpes simplex virus. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Virology (1996), Lippincott-Raven Publishers, Philadelphia, PA 2297-2342
4. De Clercq E. Antiviral drugs in clinical use. J Clin Virol 30 (2004) 115-133
5. Mertz G.J. Herpes virus simplex. In: Galasso G.J., Whitley R.J., and Merigan T.C. (Eds). Antiviral agents and viral disease of man (1990), Raven Press, New York, NY 265-300
6. Rossi L., Brandi G., Schiavano G.F., Balestra E., Millo E., Scarfì S., et al. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir. AIDS Res Hum Retroviruses 14 (1998) 435-444
7. Magnani M., Rossi L., Brandi G., Schiavano G.F., Montroni M., and Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA 89 (1992) 6477-6481
8. Brandi G., Schiavano G.F., Balestra E., Tavazzi B., Perno C.-F., and Magnani M. The potency of acyclovir can be markedly different in different cell types. Life Sci 69 (2001) 1285-1290
9. Weller S., Blumm M., Doucette M., Burnette T., Cederberg D.M., De Miranda P., et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single, and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54 (1993) 595-605
10. De Clercq E., and Field H.J. Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 147 (2006) 1-11
11. Van Aerschot A.V. Oligonucleotides as antivirals: dream or realistic perspective?. Antiviral Res 71 (2006) 307-316
12. Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert Opin Invest Drugs 14 (2005) 135-161
13. Firestine S.M. Recent advances in herpes simplex virus antiviral therapies. Expert Opin Ther Pat 14 (2004) 1139-1151
14. Rossi L., Serafini S., Franchetti P., Cappellacci L., Fraternale A., Casabianca A., et al. Targeting nucleoside dimers containing antiviral nucleosides. Curr Med Chem Anti-Infect Agents 4 (2005) 37-54
15. Griffiths A., and Coen D.M. An unusual internal ribosome entry site in the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 102 (2005) 9667-9672